Aspen Neuroscience Announces Appointment of Damien McDevitt, PhD as President and Chief Executive Officer Company Poised for Next Stage of Growth News provided by Share this article Share this article SAN DIEGO, Jan. 25, 2021 /PRNewswire/ -- Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson's disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer. Dr. McDevitt will also be joining the company's board of directors. Damien McDevitt, PhD, President & CEO of Aspen Neuroscience "We are excited to welcome Damien to Aspen Neuroscience at a pivotal moment of growth and development for the company," said Faheem Hasnain, Aspen Board Chairman. "His experience leading global teams through transformational periods will be critical to Aspen as we move into this new stage."